CYP8B1 mutation carriers showed decreased total cholesterol/HDL-C and APOB/APOA-I ratios, suggesting that CYP8B1 inhibition may reduce type 2 diabetes without proatherogenic lipid changes. Here, APOA1 is linked to type 2 diabetes mellitus.